Radezolid, also known as RX-1741, is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).
MedKoo Cat#: 535725
Name: Radezolid hydrochloride
CAS#: 869884-77-5 (HCl)
Chemical Formula: C22H24ClFN6O3
Exact Mass: 474.1582
Molecular Weight: 474.92
Elemental Analysis: C, 55.64; H, 5.09; Cl, 7.46; F, 4.00; N, 17.70; O, 10.11
The following data is based on the product molecular weight 474.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |